ライフサイエンスコーパス: phospholipase A2

1 ry enzymes (ciclooxygenase, lipoxygenase and phospholipase A2).

2 imulated TRPV4 opening through activation of phospholipase A2.

3 ive oral inhibitor of lipoprotein-associated phospholipase A2.

4 ting Ca(2+) signals that were independent of phospholipase A2.

5 s also referred to as lipoprotein-associated phospholipase A2.

6 e, secretory sphingomyelinase, and secretory phospholipase A2.

7 ell as HDL remodeling by group IIa secretory phospholipase A2.

8 PAF-AH2, an oxidized-phospholipid-selective phospholipase A2.

9 crosis factor-alpha, C-reactive protein, and phospholipase A2.

10 ipid as a novel substrate of honey bee venom phospholipase A2.

11 ts and reduced the activation of cytoplasmic phospholipase A2.

12 ase D2 and diacylglycerol kinase rather than phospholipase A2.

13 osolic phospholipase A2, calcium-independent phospholipase A2, 12/15 and 5-lipoxygenase) is expressed

14 Phospholipase A2/5-lipoxygenase/leukotriene-B4 (PLA2/5-L

15 o 0.55, p<0.0001) and lipoprotein-associated phospholipase A2 (-52.2 ng/mL, 95% CI -70.4 to -34.0, vs

16 Blocking of phospholipase A2 abrogated C-reactive protein dissociati

17 evels of prostaglandin E2 The non-functional phospholipase A2-activating protein and the associated n

18 a loss of function sequence variation in the phospholipase A2-activating protein encoding gene (PLAA)

19 induced [Formula: see text] signals required phospholipase A2 activation.

20 ted cell membranes, which is generated after phospholipase A2 activation.

21 se cleavages disrupt both the peroxidase and phospholipase A2 activities of Prdx6.

22 l or Prdx6-D140A-knock-in mice that lack the phospholipase A2 activity (PLA2) of Prdx6; addition of e

23 Increased cytosolic phospholipase A2 activity and lyso-phosphatidylcholine (

24 easurement of prostaglandin E2 and cytosolic phospholipase A2 activity in membrane fractions of fibro

25 ically with ubiquitin to greatly enhance the phospholipase A2 activity of ExoU.

26 The phospholipase A2 activity of peroxiredoxin 6 modulates N

27 Treatment with PEDF activates the phospholipase A2 activity of the PEDF-receptor (PEDF-R)

28 Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vu

29 onses are elicited through lipid products of phospholipase A2 activity that acts on the membrane phos

30 ExoU is a potent cytotoxin with phospholipase A2 activity that causes rapid necrotic dea

31 ly one type of capsid protein that lacks the phospholipase A2 activity that has been implicated as a

32 es to the plasma membrane, where it uses its phospholipase A2 activity to lyse infected cells.

33 ane of eukaryotic cells, where it exerts its phospholipase A2 activity upon interacting with ubiquiti

34 th a PPARalpha activator increased secretory phospholipase A2 activity, which likely accounts for acc

35 tics of the payload discharge appeared to be phospholipase A2 activity-dependent, as determined by me

36 hospholipases, which have been shown to have phospholipase A2 activity.

37 red by the HDL oxidative-inflammatory index; phospholipase A2 activity; and sphingosine-1-phosphate,

38 r levels of hsCRP and lipoprotein-associated phospholipase A2 after AMI compared with men, and this r

39 doxin 6 (Prdx6), a bifunctional protein with phospholipase A2 (aiPLA2) and GSH peroxidase activities,

40 tion of an intracellular interaction between phospholipase A2 and a mechanosensitive channel present

41 2+) release from internal stores, activating phospholipase A2 and generating vasodilatory arachidonic

42 Both secretory phospholipase A2 and lipoprotein-associated phospholipas

43 Selective inhibitors of secretory phospholipase A2 and lipoprotein-associated phospholipas

44 eding with clinical outcome trials secretory phospholipase A2 and lipoprotein-associated phospholipas

45 ugs (NSAIDs), which are potent inhibitors of phospholipase A2 and play a role in the pathogenesis of

46 small ubiquitin-like modifier (SUMO) domain, phospholipase A2 and PrsW-family protease domain.

47 -arrestin1-dependent activation of cytosolic phospholipase A2 and release of arachidonate, the precur

48 t, by an ATP inhibitor, and by inhibitors of phospholipase-A2 and -C.

49 While phospholipases A2 and C have been recently shown to medi

50 Phospholipases A2 and D had no effect on SHFV entry.

51 serum amyloid protein A), NPS-PLA2 (secreted phospholipase A2), and CA6 (carbonic anhydrase 6).

52 ent alpha1G subtype Ca2+ channels, cytosolic phospholipase A2, and epoxyeicosatrienoic acids.

53 embrane phospholipids by group IVA cytosolic phospholipase A2, and its conversion to bioactive lipoxi

54 Tgm2, group 10 secretory phospholipase A2, and LT enzymes in NHBEs and nasal poly

55 cell adhesion molecule 1 (VCAM-1), secretory phospholipase A2, and malondialdehyde and hydroxyalkenal

56 ANP, myeloperoxidase, lipoprotein-associated phospholipase A2, and oxidized low-density lipoprotein w

57 ion is the liberation of arachidonic acid by phospholipase A2, and the cytosolic phospholipase A2 (cP

58 Glial TRPV4 signals were phospholipase A2- and cytochrome P450-dependent, charact

59 obtained for nonaged complexes of group-VIII phospholipase A2 are compared to those obtained for othe

60 phospholipase A2 and lipoprotein-associated phospholipase A2 are potential candidates for reducing r

61 ing of beta-arrestin1 to activated cytosolic phospholipase A2 as well as beta-arrestin1-dependent act

62 d on a denatured form of the major allergen, phospholipase A2, associated with microbubbles (PLA2dena

63 hetic enzymes includes (1) the activation of phospholipase A2 at the plasma membrane, resulting in a

64 c activity of soluble lipoprotein-associated phospholipase A2; at CYP2F1, with higher plasma interleu

65 gene encodes a group VIA calcium-independent phospholipase A2 beta enzyme that selectively hydrolyses

66 Similarly, annexin A5 and phospholipase A2 blocked >95% of myosin-supported activi

67 cid after activation of the CB2 receptor and phospholipase A2 by lenabasum.

68 DX6 or inhibition of its calcium-independent phospholipase A2 (Ca(2+)-iPLA2) activity by MJ33 on fert

69 RvD1 biosynthetic machinery (e.g., cytosolic phospholipase A2, calcium-independent phospholipase A2,

70 at a number of oxygenated CL species undergo phospholipase A2-catalysed hydrolysis and thus generate

71 The lipid modifier phospholipase A2 catalyzes the hydrolysis of phospholipi

72 gnaling through the NMDA receptor, cytosolic phospholipase A2, COX-2, and mPGES-1 increases P-gp prot

73 (COX-2)/prostaglandin E2 signaling cascade (phospholipase A2, COX-2, multidrug resistance protein 4,

74 nsis-infected macrophages requires cytosolic phospholipase A2 (cPLA(2)), cyclooxygenase 2 (COX-2), an

75 s study was to investigate whether cytosolic phospholipase A2 (cPLA2 ), an important isoform of PLA2

76 ls of MYC, we found an increase in cytosolic phospholipase A2 (cPLA2) activity with a preferential re

77 GPIb-IX-induced phosphorylation of cytosolic phospholipase A2 (cPLA2) and consequent thromboxane A2 (

78 gs exist regarding the function of cytosolic phospholipase A2 (cPLA2) and its role in membrane regula

79 ctivates the enzymatic activity of cytosolic phospholipase A2 (cPLA2) as at-tested to by arachidonic

80 the relatively lower expression of cytosolic phospholipase A2 (cPLA2) in H596 cells than that of A549

81 he interaction of the C2 domain in cytosolic phospholipase A2 (cPLA2) with the CARD domain in mitocho

82 cts the expression and activity of cytosolic phospholipase A2 (cPLA2), cyclooxygenase-2 (COX-2), and

83 Tissue damage activates cytosolic phospholipase A2 (cPLA2), releasing arachidonic acid (AA

84 released during seizures activates cytosolic phospholipase A2 (cPLA2), resulting in P-gp and BCRP ove

85 tease-activated receptors 1 and 4, cytosolic phospholipase A2 (cPLA2), Src tyrosine kinases, p38 MAPK

86 mediated activation of the calcium-dependent phospholipase A2 (cPLA2).

87 AA) from membrane phospholipids by cytosolic phospholipase A2 (cPLA2).

88 acid by phospholipase A2, and the cytosolic phospholipase A2 (cPLA2)alpha isoform has been specifica

89 The role of Group IVA cytosolic phospholipase A2 (cPLA2alpha) activation in regulating m

90 Group IVA cytosolic phospholipase A2 (cPLA2alpha) acts as a bridge in this c

91 hown to require activation of host cytosolic phospholipase A2 (cPLA2alpha) by Loops1 and 2 but not 3.

92 fter pharmacological inhibition of Group IVA phospholipase A2 (cPLA2alpha) or down-regulation of cera

93 compelling evidence that group IVA cytosolic phospholipase A2 (cPLA2alpha) targets arachidonic acid-c

94 -of-function mutation in group IVA cytosolic phospholipase A2 (cPLA2alpha).

95 es through activation of group IVA cytosolic phospholipase A2 (cPLA2alpha).

96 crophages, activation of group IVA cytosolic phospholipase A2(cPLA2alpha) by calcium- and mitogen-act

97 Cytosolic phospholipases A2 (cPLA2s) consist of a family of calciu

98 The inhibition of phospholipase A2, cyclooxygenase, or blockade of the thr

99 E2 (PGE2) via a calcium-dependent cytosolic phospholipase A2/cyclooxygenase-mediated mechanism.

100 Group IVA phospholipase A2 [cytosolic phospholipase A2alpha (cPLA2

101 at localizes and aggravates inflammation via phospholipase A2-dependent dissociation of circulating p

102 and free fatty acid content and a cytosolic phospholipase A2-dependent increase in formation of lipi

103 xperiments confirmed ANXA1 as an independent phospholipase A2-dependent monocyte recruiter; congruent

104 B. p67(phox) terminates the phospholipase A2-derived signal for activation of NADPH

105 The importance of the phospholipase A2 domain located within the unique N term

106 hile the PmMDV VP sequence lacks a canonical phospholipase A2 domain, the structure of an EDTA-treate

107 ly when T3SS-positive bacteria expressed the phospholipase A2 effector Exotoxin U (ExoU).

108 ExoU is a potent phospholipase A2 effector protein secreted by the type I

109 In contrast, the levels of phospholipase A2, enkephalin, PSD-95, synaptophysin, or

110 Phospholipase A2 enzymes (PLA2) are known to mediate mem

111 Phospholipase A2 enzymes are ubiquitously distributed th

112 We studied the expression of multiple phospholipase A2 enzymes in human macrophages and the ef

113 d FA production in oilseeds and suggest that phospholipase A2 enzymes rather than LPCAT mediate the h

114 Finally, phosphorylated-phospholipase A2 expression was significantly higher in

115 phospholipase A2 (Lp-PLA2), a member of the phospholipase A2 family of enzymes, produced predominant

116 We have documented the expression of the phospholipase A2 family of genes in aortic valves by usi

117 Because these cells contain multiple phospholipase A2 forms, the challenge is to elucidate th

118 on, soman, and sarin complexes of group-VIII phospholipase A2 from bovine brain.

119 urons caused the dissociation of cytoplasmic phospholipase A2 from PrP-containing membrane rafts and

120 hich may (i) release VP1 amino acids for its phospholipase A2 function for endosomal escape and nucle

121 Phospholipase A2s generate lipid mediators that constitu

122 At least 11 phospholipase A2 genes were found at significant levels

123 The Group IVA cytosolic phospholipase A2 (GIVA cPLA2) is a key provider of subst

124 Cytosolic phospholipase A2 (GIVA cPLA2) is the only PLA2 that exhi

125 Group IVA cytosolic phospholipase A2 (GIVA cPLA2) is the rate-limiting provi

126 Here we identify epithelial-cell-derived phospholipase A2 group 1B (PLA2g1B) as a host-derived en

127 tion significantly impairs the expression of phospholipase A2 group 7 (Pla2g7) in macrophages, which

128 ically engineered mice lacking expression of phospholipase A2 group 7 (PLA2G7), an enzyme that specif

129 In patient plasma, we identified phospholipase A2 group IB (PLA2G1B) as the key molecule

130 Secretory phospholipase A2 group IIa (PLA2g2a) is associated with

131 Secretory phospholipase A2 group IIA (sPLA2-IIA) has been identifi

132 Secretory phospholipase A2 group IIA (sPLA2-IIA) plays an importan

133 Eicosanoids, derived from the cytosolic phospholipase A2 group IVA (cPLA2alpha) activation, are

134 A-->G variant (rs12746200) of the cytosolic phospholipase A2 group IVA gene (PLA2G4A), which encodes

135 (INAD), most commonly caused by mutations of phospholipase A2 group VI gene (PLA2G6), but alleles of

136 04, n >/=5/group) for five other NBIA genes, phospholipase A2 group VI, fatty acid 2-hydroxylase, cer

137 Secreted phospholipase A2 group X (sPLA2-X) plays a key role in r

138 t Pla2g5-null mice lacking group V secretory phospholipase A2 (gV-sPLA2) showed reduced eosinophilic

139 Group X secretory phospholipase A2 (GX sPLA2) hydrolyzes mammalian cell me

140 Group X secretory phospholipase A2 (GX sPLA2) potently hydrolyzes membrane

141 Human group IIA secreted phospholipase A2 (hGIIA) promotes tumor growth and infla

142 ipoproteins AI and B, lipoprotein-associated phospholipase A2, homocysteine or folate, some with larg

143 In particular, phospholipase A2 homologues appear to play an important

144 drion is an endogenous substrate of secreted phospholipase A2 IIA (sPLA2-IIA), a phospholipase otherw

145 d through the concerted activity of secreted phospholipase A2 IIA (sPLA2-IIA), present in inflammator

146 ense oligonucleotides (one against secretory phospholipase A2 IIa and the other against cytosolic pho

147 red remodeling of HDL by group IIa secretory phospholipase A2 in concert with cholesterol ester trans

148 phospholipase A2 and lipoprotein-associated phospholipase A2 inhibition.

149 Cells treated with the cytosolic phospholipase A2 inhibitor, cPLA2alpha, had no effect on

150 phospholipase A2 and lipoprotein-associated phospholipase A2 inhibitors hold promise for the reducti

151 des the rationale for the development of the phospholipase A2 inhibitors varespladib methyl and darap

152 exposure to fatty acid-free BSA or cytosolic phospholipase A2 inhibitors.

153 igation of this novel lipoprotein-associated phospholipase A2 inhibitory mechanism for the treatment

154 which encodes group VIA calcium-independent phospholipase A2 (iPLA(2)beta), were recently identified

155 ntify roles of rab6a and calcium-independent phospholipase A2 (iPLA2) in Golgi enzyme recycling, and

156 Group VIA phospholipase A2 (iPLA2beta) affects beta-cell sensitivi

157 Activation of group VIA phospholipase A2 (iPLA2beta) causes accumulation of arac

158 acrophages, the Ca(2+)-independent group VIA phospholipase A2 (iPLA2beta) has not been clearly define

159 Here we demonstrate that group VIA phospholipase A2 (iPLA2beta) plays a pivotal role in Ang

160 inhibition of the group VIA Ca2+-independent phospholipase A2 (iPLA2beta), associated with an increas

161 Cytosolic phospholipase A2 is a key regulator of blood-brain barri

162 One of these, a phospholipase A2 isoenzyme, is capable of releasing a nu

163 idylcholine (Lyso-PC) by activating multiple phospholipase A2 isoforms via CD36.

164 Lipoprotein-associated phospholipase A2 levels in the second, third, and fourth

165 s and amphipathic UC from the bilayer to the phospholipase A2-like and esterification active sites of

166 of a heteromeric complex between Kunitz- and phospholipase-A2-like proteins that together function as

167 Lipoprotein-associated phospholipase A2 (Lp PLA2) is postulated to occupy a key

168 pase A2 (sPLA(2)) and lipoprotein-associated phospholipase A2 (Lp-PLA(2)) are enzyme biomarkers of in

169 vated levels of human lipoprotein-associated phospholipase A2 (Lp-PLA2) are associated with cardiovas

170 Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be i

171 Lipoprotein-associated phospholipase A2 (Lp-PLA2) hydrolyses oxidized low-densi

172 presence and role of lipoprotein-associated phospholipase A2 (Lp-PLA2) in calcific aortic valve dise

173 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a risk factor for coronary

174 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an emerging biomarker of c

175 10% reduction in the lipoprotein-associated phospholipase A2 (Lp-PLA2) level was seen in the statin

176 Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels predict incident coron

177 tients that increased lipoprotein-associated phospholipase A2 (Lp-PLA2) mass or activity is associate

178 Lipoprotein-associated phospholipase A2 (Lp-PLA2), a member of the phospholipas

179 )-VI isoform), plasma lipoprotein-associated phospholipase A2 (Lp-PLA2), Mercodia oxidized LDL (OxLDL

180 ascular inflammation (lipoprotein-associated phospholipase A2 [Lp-PLA2]) were compared.

181 Lysosomal phospholipase A2 (LPLA2) and lecithin:cholesterol acyltr

182 ike 2 protein (PLBL2) and Group XV lysosomal phospholipase A2 (LPLA2).

183 Lysosomal phospholipase A2 (LPLA2, group XV phospholipase A2) resi

184 ive protein (CRP) and lipoprotein-associated phospholipase A2 (LpPLA2).

185 esterol, adiponectin, lipoprotein-associated phospholipase A2 mass and activity, monocyte chemoattrac

186 I, lipoprotein(a), or lipoprotein-associated phospholipase A2 mass to risk scores containing total ch

187 protein(a), 4.1%; and lipoprotein-associated phospholipase A2 mass, 2.7% of people to a 20% or higher

188 I, 0.0010-0.0026) for lipoprotein-associated phospholipase A2 mass.

189 Finally, we propose that cytosolic phospholipase A2 may be a potential source of these hydr

190 Phospholipase A2s mediate the rate-limiting step in the

191 correlated with altered COX-2 and cytosolic phospholipase A2 messenger RNA levels in the joints of C

192 Moreover, the phospholipase A2 motif in the VP1 unique region was also

193 iated with changes in lipoprotein-associated phospholipase A2 (n = 10; r = 0.67; P = .03).

194 on could be detected using phospholipase A1, phospholipase A2, or phospholipase C, allowing for a rel

195 ional enzyme with glutathione peroxidase and phospholipase A2 (PLA(2)) activities, participates in th

196 ls specific for the major bee venom allergen phospholipase A2 (PLA) were isolated from beekeepers who

197 Phospholipase A2 (PLA)-specific B cells were identified

198 ined by demonstrating that bee venom-derived phospholipase A2 (PLA2) activates T cells through genera

199 Phospholipase A2 (PLA2) activity has been shown to be in

200 While some patatin-like proteins have phospholipase A2 (PLA2) activity, recombinant TgPL1 puri

201 ybean seeds and positively characterised for phospholipase A2 (PLA2) activity, suggesting their plaus

202 tical methods have been developed to monitor phospholipase A2 (PLA2) activity.

203 For ED, phospholipase C (PLC), phospholipase A2 (PLA2) and a mixture of phospholipases

204 Here, we propose that 2 enzymes-phospholipase A2 (PLA2) and ectonucleotide pyrophophatas

205 We investigated the role of phospholipase A2 (PLA2) and the effects of PLA2 products

206 In both plants, an elicitor-responsive phospholipase A2 (PLA2) at the plasma membrane generates

207 ond premicellar complex of pig pancreatic IB phospholipase A2 (PLA2) can be considered a proxy for in

208 the demonstration that lipid enzymes such as phospholipase A2 (PLA2) contain allosteric activator sit

209 Phospholipase A2 (PLA2) enzymes act at the membrane-wate

210 Phospholipase A2 (PLA2) enzymes, which catalyze the hydr

211 PURPOSE OF REVIEW: The phospholipase A2 (PLA2) family of proteins includes lipo

212 Inhibition of phospholipase A2 (PLA2) has long been considered for tre

213 ployed to quantify the catalytic activity of phospholipase A2 (PLA2) in both pure and complex biologi

214 ts were pretreated (i.c.v) with mepacrine [a phospholipase A2 (PLA2) inhibitor], ibuprofen [a nonsele

215 Phospholipase A2 (PLA2) is a conserved component of veno

216 In addition, phospholipase A2 (PLA2) is highly expressed in psoriatic

217 The development of inhibitors for phospholipase A2 (PLA2) is important in elucidating the

218 A phospholipase A2 (PLA2) is thought to be involved in the

219 s are important vascular regulators, but the phospholipase A2 (PLA2) isoforms supporting their produc

220 ions of S1P in vitro In addition, inhibiting phospholipase A2 (PLA2) or lipoxygenase (Lox) blocks che

221 n after lung challenge with S. pneumoniae As phospholipase A2 (PLA2) promotes the release of AA, we i

222 of cancer cells was critically dependent on phospholipase A2 (PLA2) to mobilize lysophospholipids an

223 The antioxidant effect of porcine pancreatic phospholipase A2 (PLA2) was previously demonstrated.

224 to evaluate the activity of Ca(2+)-dependent phospholipase A2 (PLA2), an inflammatory protein that (i

225 at are involved in the inflammatory process: phospholipase A2 (PLA2), cyclooxygenase 2 (COX-2), throm

226 le of sequestering and neutralizing venomous phospholipase A2 (PLA2), we demonstrate that broad-spect

227 that gossypol rapidly increased activity of phospholipase A2 (PLA2), which led to an increase in cyt

228 hate (cAMP) and a subsequent inactivation of phospholipase A2 (PLA2), whose metabolites are known to

229 Phospholipase A2 (PLA2)-dependent pathways are important

230 Among snakes, phospholipase A2 (PLA2)-related toxins have evolved in d

231 The phospholipase A2 (PLA2)activity of phosphorylated peroxi

232 Phospholipases A2 (PLA2) catalyze the hydrolysis reactio

233 CR and two isoforms of the allergen Api m 1 (phospholipase A2: PLA2) in HBV.

234 Adipose-specific phospholipase A2 (PLA2G16) was recently identified as a

235 ), two in apolipoprotein B (APOB) and one in phospholipase A2 (PLA2G4A) that significantly associated

236 eractions between the promoters of COX-2 and phospholipase A2 (PLA2G4A), an adjacent pro-inflammatory

237 l. (2017) provide intriguing evidence that a phospholipase A2 (Pla2gb1) produced by epithelial cells

238 The M-type receptor for phospholipase A2 (PLA2R1) is the major target antigen in

239 oop by which LPI is synthesized by cytosolic phospholipase A2, pumped out of the cell by the ATP-bind

240 tment effect, circulating nephritogenic anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies an

241 long the glomerular basement membrane (GBM), phospholipase A2 receptor (PLA2R) and thrombospondin typ

242 The phospholipase A2 receptor (PLA2R) and thrombospondin typ

243 The characterization of the phospholipase A2 receptor (PLA2R) as the major target an

244 Phospholipase A2 receptor (PLA2R) is a member of the man

245 The M-type phospholipase A2 receptor (PLA2R) is expressed in podocy

246 Secretory phospholipase A2 receptor (PLA2R) is the target antigen

247 extracted IgG was determined by ELISA using phospholipase A2 receptor (PLA2R) or Gd-IgA1 as antigen.

248 We sought to determine the utility of phospholipase A2 receptor (PLA2R) staining for the detec

249 complement-fixing IgG4 autoantibodies to the phospholipase A2 receptor (PLA2R).

250 pathy (IMN) have IgG4 autoantibodies against phospholipase A2 receptor (PLA2R).

251 ting serum autoantibodies against the M-type phospholipase A2 receptor (PLA2R-AB) are a key biomarker

252 wed that genetic variants in an HLA-DQA1 and phospholipase A2 receptor (PLA2R1) allele associate most

253 The phospholipase A2 receptor (PLA2R1) is the major autoanti

254 The phospholipase A2 receptor (PLA2R1) is the major autoanti

255 le is known about the biological role of the phospholipase A2 receptor (PLA2R1) transmembrane protein

256 is known about the physiological role of the phospholipase A2 receptor (PLA2R1).

257 tly discovered podocyte antigens: the M-type phospholipase A2 receptor 1 (PLA2R) and thrombospondin t

258 Phospholipase A2 receptor 1 (PLA2R) is a target autoanti

259 very of the major target antigen, the M-type phospholipase A2 receptor 1 (PLA2R).

260 bodies against the podocyte surface antigens phospholipase A2 receptor 1 (PLA2R1) and the recently id

261 s associated with autoantibodies against the phospholipase A2 receptor 1 (PLA2R1).

262 ephropathy (MN) along with the major antigen phospholipase A2 receptor 1 (PLA2R1).

263 01) per gram, P = 0.010] and those with anti-phospholipase A2 receptor antibodies [hazard ratio = 3.7

264 ptor (FcRY) is the ortholog of the mammalian phospholipase A2 receptor, a mannose receptor family mem

265 oxisomal trans-2-enoyl-coenzyme A reductase, phospholipase A2 receptor, protein kinase C zeta type, t

266 culating autoantibodies targeting the M-type phospholipase A2 receptor-1 (PLA2R) on the surface of gl

267 Lysosomal phospholipase A2 (LPLA2, group XV phospholipase A2) resides in the endocytic system, the m

268 e ExoU type III secretion enzyme is a potent phospholipase A2 secreted by the Gram-negative opportuni

269 Phospholipase A2-specific IgG4-switched memory B cells e

270 Secretory phospholipase A2 (sPLA(2)) and lipoprotein-associated ph

271 The group IIA secretory phospholipase A2 (sPLA(2)-IIA) has been studied extensiv

272 , LTE4 , PGD2 , and PGE2 , plasma secretory phospholipase A2 (sPLA2 ), and 11beta prostaglandin F2al

273 Group IB secretory phospholipase A2 (sPLA2 IB), which is one of the ligands

274 Observational studies report that secretory phospholipase A2 (sPLA2) activity is a marker for corona

275 Paneth cell antimicrobial molecule secretory phospholipase A2 (sPLA2) and the goblet cell glycoprotei

276 Secretory phospholipase A2 (sPLA2) enzymes are considered to play

277 Secretory phospholipase A2 (sPLA2) generates bioactive phospholipi

278 hase of the inflammatory response, secretory phospholipase A2 (sPLA2) reaches its maximum levels in p

279 ays, we found expression levels of secretory phospholipase A2 (sPLA2), lysophospholipid acyltransfera

280 sought to investigate the role of secretory phospholipase A2 (sPLA2)-IIA in cardiovascular disease.

281 tional screen, we have identified a secreted phospholipase A2 (sPLA2)-like protein, BomoTx, from the

282 ural rigidity in the inhibition of secretary phospholipase A2 (sPLA2).

283 The type IIA secretory phospholipase A2 (sPLA2-IIA) is a host protein endowed w

284 analyze the role of human group IIA secreted phospholipase A2 (sPLA2-IIA), a bactericidal enzyme indu

285 strong upregulation of the secreted group V phospholipase A2 (sPLA2-V), both at the mRNA and protein

286 Here, we identify secreted phospholipases A2 (sPLA2s) as stem cell niche factors wi

287 We report a series of inhibitors of secreted phospholipases A2 (sPLA2s) based on substituted indoles,

288 We have previously shown that secreted phospholipases A2 (sPLA2s) from animal venoms inhibit th

289 ity to induce prostaglandin E2 and cytosolic phospholipase A2 synthesis in patients' fibroblasts.

290 ivating factor acetylhydrolase (PAF-AH) is a phospholipase A2 that inactivates potent lipid messenger

291 stence in two evolutionary distant plants of phospholipases A2 that discriminate "self-made" from "fo

292 of the phospholipids are removed from CcO by phospholipase A2 (the half-life decreases at 37 degrees

293 d a novel cardiolipin hydrolysis reaction by phospholipase A2 to form diacylated cardiolipin progress

294 on, the use of phospholipases, in particular phospholipase A2, was essential to define the fatty acid

295 e protein (hsCRP) and lipoprotein-associated phospholipase A2 were measured 1 month after AMI.

296 fungitoxic metabolites through the action of phospholipase A2, which is enhanced in bacterized plants

297 kinase-dependent activation of the cytosolic phospholipase A2, which releases arachidonic acid from m

298 yclooxygenase-2 and phosphorylated cytosolic phospholipase A2, which was reflected in prostaglandin E

299 mediated activation of a calcium independent phospholipase A2 with resultant synthesis of lysophospha

300 adult mice expressed more group 10 secretory phospholipase A2, Wnt5a, and transglutaminase 2 (Tgm2).